ApoM and Major Adverse Cardiovascular Events in Chronic Kidney Disease: A Prospective Cohort Study

• DOI: 10.1161/atvbaha.124.322367
• Publication Date: 2025-03-06T10:00:48Z
• Authors: Julia T. Stadler; Andrea Borenich; Line Stattau Bisg...; Sasha S. Bjergfelt; Sarunja Vijayakumar; Line Melholt; Insa E. Emrich; Ditte Hansen; Susanne Bro; Christina Christo...; Gunnar H. Heine; Gunther Marsche

Cardiovascular disease is the leading cause of mortality in patients with chronic kidney (CKD). APOM plays a critical role reverse cholesterol transport by facilitating formation pre-β-HDL (high-density lipoprotein) and enabling binding S1P (sphingosine-1-phosphate) to HDL, complex involved several antiatherogenic processes. In this study, we sought investigate potential association between plasma levels risk adverse cardiovascular outcomes individuals CKD. Plasma were quantified using sandwich ELISA-based assay. measured high-performance liquid chromatography. The primary end point was composite major events (MACE) all-cause mortality. secondary analysis CARE FOR HOMe study (Cardiovascular Renal Outcome CKD 2-4 Patients-The Fourth Homburg Evaluation), 463 nondialysis stages G2 G4 included. exhibited significant inverse MACE (standardized hazard ratio, 0.60 [95% CI, 0.49-0.75]; P<0.001) 0.63 0.48-0.83]; P<0.001). This remained robust after adjusting for established renal factors. These findings further corroborated an independent cohort 822 from Copenhagen study. showed univariable analyses; however, relationship lost statistical significance multivariable adjustments. Our demonstrate low increased results suggest that may play protection vulnerable population.